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Abstract
Upregulated ERK1/2 activity is correlated with androgen receptor (AR) downregulation in certain
prostate cancer (PCa) that exhibits androgen deprivation-induced neuroendocrine differentiation,
but its functional relevance requires elucidation. We found that sustained ERK1/2 activation using
active Raf or MEK1/2 mutants is sufficient to induce AR downregulation at mRNA and protein
levels in LNCaP. Downregulation of AR protein, but not mRNA, was blocked by proteasome
inhibitors, MG132 and bortezomib, indicating that the pathway regulation is mediated at multiple
points. Ectopic expression of a constitutively active AR inhibited Raf/MEK/ERK-mediated
regulation of the differentiation markers, neuron-specific enolase and neutral endopeptidase, and
the cyclin-dependent kinase inhibitors, p16INK4A and p21CIP1, but not Rb phosphorylation and
E2F1 expression, indicating that AR has a specific role in the pathway-mediated differentiation
and growth inhibitory signaling. However, despite the sufficient role of Raf/MEK/ERK, its
inhibition using U0126 or ERK1/2 knockdown could not block androgen deprivation-induced AR
downregulation in an LNCaP neuroendocrine differentiation model, suggesting that additional
signaling pathways are involved in the regulation. We additionally report that sustained Raf/MEK/
ERK activity can downregulate full length as well as hormone binding domain-deficient AR
isoforms in androgen-refractory C4-2 and CWR22Rv1, but not in LAPC4 and MDA-PCa-2b. Our
study demonstrates a novel role of the Raf/MEK/ERK pathway in regulating AR expression in
certain PCa types and provides an insight into PCa responses to its aberrant activation.
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Introduction
The Raf/MEK/extracellular signal-regulated kinase (ERK) pathway has pivotal roles in
controlling cell survival, cell cycle progression and differentiation, and its dysregulated
signaling is a central signature of many epithelial cancers [1, 2]. The Ser/Thr kinase Raf (c-
Raf-1, Raf-B or Raf-A) activates the dual-specificity kinases MEK1 and MEK2 which, in
turn, sequentially phosphorylate Tyr and Thr in the activation loop of the ubiquitously
expressed Ser/Thr kinases ERK1 and its homologue ERK2. Activated ERK1/2 mediates
diverse biological processes by activating/inactivating a wide variety of proteins, and
different magnitudes of its activity can lead to distinct biological outputs [1]. Upregulated
activity of the MEK/ERK pathway has been shown for its association with progression and
poor prognosis of prostate cancer (PCa). For example, ERK1/2 phosphorylation is often
detected in correlation with increased tumor grade of primary or metastatic PCa and tumor
relapse after therapy [3–6]. In addition, although not frequent, mutations or chromosomal
rearrangements of Raf genes that can confer neoplastic Raf kinase activity are detected in
human PCa [7–11]. Together, these observations support pathogenetic relevance of the
MEK/ERK pathway in prostate tumorigenesis and underscore the need for better
understanding of the role of the pathway in PCa cells.
Androgen receptor (AR) is a member of the nuclear receptor superfamily that functions as a
ligand-dependent nuclear transcription factor [12]. AR can control the growth regulatory and
differentiation pathways in prostate epithelial cells, and its altered expression or signaling is
a pivotal event in the carcinogenesis of prostate epithelium [13, 14]. While increased AR
expression is a key feature of a subpopulation of castration-resistant PCa [15], loss of AR
expression, accompanied by decreased mitotic activity, is also detected in certain PCa types
that exhibit neuroendocrine (NE) differentiation [16, 17]. NE-differentiated cells in PCa are
supposed to contribute to castration resistance of neighboring non-NE PCa cells by
activating paracrine signaling mechanisms [18, 19]. Although the origin of NE differentiated
cells in PCa is not fully understood, literatures support the possibility that prostate
adenocarcinoma cells transdifferentiate into NE-like phenotype in response to androgen
depletion. For example, NE differentiated cells in tumor lesions show identical genetic
profiles with adjacent exocrine PCa cells [20], and certain human PCa cell lines, including
LNCaP, CWR22 and PC310, exhibit expression of various makers for NE differentiation in
vitro as well as in vivo in response to hormone withdrawal [21–23]. It has been shown that
AR downregulation is required for NE differentiation [24], but the signaling mechanisms
that underlie AR downregulation upon androgen withdrawal are as yet unclear.
Upregulated ERK1/2 activity is detected in NE cells in PCa as well as in NE-differentiating
PCa cell lines while various stimulations that activate the Raf/MEK/ERK pathway can
induce NE differentiation of PCa cells in in vitro and in vivo environments [19, 25].
Furthermore, ectopic expression of a constitutively active MEK1 mutant was indeed
sufficient to mediate expression of NE markers in LNCaP cells [21]. We recently reported
that sustained Raf/MEK/ERK activation can induce cell cycle arrest in G0/G1 phase in
LNCaP [26], which may implicate the pathway in decreased mitotic activity of NE-
transdifferentiating PCa cells. Together, these results indicate an involvement of Raf/MEK/
ERK signaling in NE differentiation of PCa cells. Given the pivotal role of AR for PCa cell
proliferation/survival and differentiation, it is conceivable that the Raf/MEK/ERK pathway
may also have a role in mediating AR downregulation. Nevertheless, this possibility has
never been addressed before.
In this study, we investigated whether the Raf/MEK/ERK pathway can mediate AR
downregulation and, thereby, decrease cell proliferation during NE differentiation of
LNCaP. We demonstrate that ERK1/2 activity and AR expression are inverse-correlated in
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an LNCaP model for hormone depletion-mediated NE differentiation and that sustained Raf/
MEK/ERK activity is sufficient to mediate AR downregulation, although not necessary. We
then examine how AR downregulation is mediated and whether it is required for the
pathway-mediated growth arrest and differentiation signaling. Additionally, we show that
the pathway can mediate AR downregulation in a subset of PCa lines regardless of androgen
sensitivity. This study reveals previously unknown roles of the Raf/MEK/ERK pathway in
PCa cells.
Materials and methods
Cell culture, generation of stable line
LNCaP (ATCC), PC3 (ATCC), Du145 (ATCC), and CWR22Rv1 (ATCC) were maintained
in phenol red-deficient RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS), 100 U of penicillin and 100 ȝg of streptomycin per ml. LAPC-4
(ATCC) was grown in Iscove’s medium with 10% FBS. MDA-Pca-2b (ATCC) was grown
in Hams F12 medium supplemented with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate,
25 ng/ml cholera toxin, 10 ng/ml epidermal growth factor, 0.005 mM phosphoethanolamine,
100 pg/ml hydrocortisone, 45 nM selenious acid, 0.005 mg/ml insulin, and 20% FBS. C4-2,
NE1.3 and NE1.8 cells were maintained in phenol red-deficient RPMI 1640 supplemented
with 10% charcoal/dextran-stripped FBS (c.s.FBS). LNCaPRaf, stably transduced with
lentivirus containing ǻRaf-1:ER, was previously described [26]. U0126, MG-132,
Lactacystin, and 4-hydroxytamoxifen were obtained from Sigma (St. Louis, MO).
Bortezomib was obtained from Selleck Chemicals (Houston, TX).
Viral infection
The lentiviral expression vector pHAGE and the lentiviral shRNA expression vector pLL3.7
(ATCC) were used as previously described [26]. Briefly, for viral production, pHAGE or
pLL3.7 was co-transfected with packaging vectors into 293T cells and the resulting
supernatant was collected after 48 h. Viral titers were determined by infecting the recipient
cell lines with serially diluted viral supernatants mixed with polybrene (Sigma) at 8 ȝg/ml
and scoring cells expressing GFP at 48 h post-infection. Cells were infected overnight and
were switched into fresh culture media.
Recombinant lentiviral constructs and RNA interference
Generation of pHAGE-GFP-MEK1CA and pHAGE-GFP-MEK2CA containing
constitutively active MEK1-R4F (ǻN3/S218E/S222D) and MEK2-KW71 (ǻN4/S222D/
S226D), respectively, were previously described [26]. pHAGE-GFP-H-RasG12V and
pHAGE-GFP-B-RafV600E contain the oncogenic human genes, H-RasG12V and B-RafV600E,
respectively. pHAGE-GFP-AAø was constructed using the hormone binding domain-
deficient AR mutant, AAø [27]. The siRNA oligomers targeting
GACCTGAATTGTATCATC (ERK1 nucleotides 801–819),
GAAACTACCTACAGTCTCT (ERK1 nucleotides 833–851),
CCAAAGCTCTGGACTTATT (ERK2 nucleotides 851–869),
GTACAGGGCTCCAGAAATT (ERK2 nucleotides 576–594), and the scrambled control
were purchased from Dharmacon (Lafayette, CO). Cells were transfected using
DharmaFECT 2 (Dharmacon) according to the manufacturer’s protocol. For stable
expression of small hairpin RNA (shRNA), pLL3.7-shRNA systems targeting ERK1
(nucleotides 801–819) or ERK2 (nucleotides 851–869) were constructed and described
previously [26].
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Quantitative real time polymerase chain reaction (qPCR)
The qPCR analysis of AR was performed using the Mx3005P™ instrument (Stratagene, La
Jolla, CA) by reverse transcription of 0.25 ȝg total RNA, and subsequent polymerase chain
reaction using a Brilliant SYBR® Green QPCR Core Reagent Kit (Stratagene, La Jolla, CA)
according to the manufacturer’s protocol. Primers were CTACATCAAGGAACTCGATC
and CTGGGTGTGGAAATAGATT (AR nucleotides 2,502–2,760) and the thermocycling
conditions were 10 min at 95°C as first denaturation step, followed by 40 cycles at 95°C for
30 seconds, 55°C for 60 seconds and 72°C for 30 seconds. As the control for normalization,
expression of phosphoglycerate kinase was measured using primers
CAGTTTGGAGCTCCTGGAAG and TGCAAATCCAGGGTCCAGTG.
Calculation of the gene copy number was carried out using comparative threshold cycle, as
previously described [28]. Briefly, the mean threshold cycle (mCT) was obtained from
triplicate amplifications during the exponential phase of amplification. Then, mCT value of
the reference gene was subtracted from mCT value of the target gene (AR) to obtain ǻCT.ǻǻCT values of each sample was calculated from corresponding CT values; where ǻǻCT =
[mCT target (normal sample) ᙐ mCT reference (normal sample)] ᙐ [mCT target (test sample) ᙐ
mCT reference (test sample)]. The calculated ǻǻCT was converted to ratio using the ratio
formula (Ratio = 2ᙐǻǻCT).
Prostate-specific antigen (PSA)-luciferase reporter assay
Cells were transfected with the PSA-luciferase reporter construct harboring 6.0 kilo base
pairs of PSA promoter DNA (obtained from Shuyuan Yeh, Univ. of Rochester) using
Lipofectamine 2000 (Invitrogen). Transfected master cultures were then divided in triplicate
into 24-well plates for further treatments, as described in the text. Cell lysates were analyzed
using the Luciferase Assay System (Promega) according to the manufacturer’s instructions.
Reporter activity data were normalized for protein concentration.
Immunoblot analysis
Cells harvested at various times were lysed in 62.5 mM Tris (pH 6.8)-2% SDS mixed with
the protease inhibitor cocktail (Sigma) that contains 4-(2-aminoethyl) benzenesulfonyl
fluoride, pepstatin A, E-64, bestatin, leupeptin, and aprotinin, and briefly sonicated before
determining the protein concentration using the BCA reagent (Pierce, Rockford, IL). 50 ȝg
of protein was resolved by SDS-PAGE, transferred to a polyvinylidene difluoride membrane
filter (Bio-Rad, Hercules, CA), and stained with Fast Green reagent (Thermo Fisher
Scientific, Waltham, MA). Membrane filters were then blocked in 0.1 M Tris (pH 7.5)-0.9%
NaCl-0.05% Tween 20 with 5% nonfat dry milk, and incubated with appropriate antibodies.
Antibodies were diluted as follows: ERK1/2, 1:2,500; phospho-ERK1/2 (Thr202/Tyr204),
1:2,500; phospho-p90RSK (Thr359/Ser363), 1:2,500; phospho-AKT/protein kinase B
(Ser473), 1:5,000; AR, 1:2,500; phospho-Rb (Ser780), 1:2,500; Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), 1:5,000 (Cell Signaling Technology, Danvers, MA); E2F1,
1:1,000; PSA, 1:1,000; neuron-specific enolase (NSE), 1:2,500; neutral endopeptidase
(NEP), 1:1,000 (Thermo Fisher Scientific); p21CIP1, 1:2,500; p27KIP1, 1:1,000 (Santa Cruz
Biotech, Santa Cruz, CA); p16INK4A, 1:2,500 (BD Bioscience, San Jose, CA). Nuclear and
cytoplasmic fractions were extracted using the nuclear extraction kit (Pierce) according to
the manufacturer’s instruction. The Supersignal West Pico and Femto chemiluminescence
kits (Pierce) were used for visualization of the signal. For densitometry, immunoblots were
scanned and analyzed using LabWorks™ (UVP BioImaging Systems, Upland, CA).
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Results
ERK1/2 activation is correlated with AR downregulation during androgen deprivation-
induced LNCaP differentiation
It was previously shown that LNCaP cells undergo NE differentiation in response to
androgen depletion when cultured in c.s.FBS-containing medium [21]. We found that AR
downregulation detected in LNCaP cells in c.s.FBS medium is also a specific response of
the cells to androgen depletion because addition of R1881 nullified the c.s.FBS effect (Fig.
1A).
To determine the role of the ERK1/2 pathway in regulating AR expression under a hormone
withdrawal condition, we analyzed the correlation between ERK1/2 activation and AR
levels in LNCaP cells, cultured in regular FBS- or c.s.FBS-containing medium for 10 days,
and their NE derivatives, NE1.3 and NE1.8. NE1.3 and NE1.8 cells, derived under a
prolonged (over 6 months) hormone-depleted culture condition, have served as a model to
study NE differentiation of PCa because they exhibit the typical characteristics of NE
differentiated PCa cells in both in vitro and in vivo microenvironments, i.e., hormone
independency, absence of AR expression and increased expression of the NE differentiation
markers, neuron-specific enolase (NSE), chromogranin B, neurotensin and parathyroid
hormone related peptide [19, 21, 25]. In addition, these LNCaP derivatives exhibited low
levels of neutral endopeptidase (NEP), which is known to antagonize NE differentiation and
castration-resistance by degrading neuropeptides in prostate cancer [29] (Fig. 1B). We found
that phosphorylation levels of the activation loop of ERK1 (T202/Y204) and ERK2 (T183/
Y185) gradually increased during LNCaP responses to hormone depletion (Fig. 1B).
Notably, about 20 and 10 fold increases in ERK1 and ERK2 phosphorylations, respectively,
were detected in the NE derivatives when compared to the parental LNCaP cells cultured in
c.s.FBS for 10 days. These increases in ERK1/2 phosphorylation were strongly correlated
with decreases in AR, PSA and NEP protein levels, and increases in NSE expression (Fig.
1B). PSA is a bona fide indicator of the AR activity as a transcriptional regulator [13]. For a
comparison, we also detected activation of AKT/protein kinase B, which is also implicated
in NE differentiation of LNCaP [30]. AKT phosphorylation was also upregulated but the
increase was mild and its correlation with AR downregulation was not as strong as ERK1/2
activation (Fig. 1B).
Sustained Raf activation is sufficient to induce AR downregulation in LNCaP cells
We determined the specific effect of MEK/ERK activation on AR expression using
ǻRaf-1:ER that is the CR3 catalytic domain of Raf-1 fused to the hormone binding domain
of the estrogen receptor [31]. ǻRaf-1:ER can be regulated by the estrogen analogue, 4-
hydroxytamoxifen, and has been useful in many studies of Raf/MEK/ERK signaling [26,
32–36]. When LNCaP cells containing ǻRaf-1:ER (LNCaPRaf) was exposed to 1 ȝM 4-
hydroxytamoxifen, cells exhibited highly increased ERK1/2 phosphorylation and
significantly decreased AR protein levels within 48 hours similarly to the levels detected in
NE1.8 cells (Fig. 2A). AR downregulation was detected not only in the cytosol but also in
the nucleus (Fig. 2B) and, consistently, not only PSA protein expression but also its
transcription was significantly decreased, as determined by the luciferase reporter containing
DNA promoter region of PSA (Fig. 2A and 2C). Consistently with the previous result that
the pathway activation is sufficient to mediate NE differentiation [21], NSE expression was
elevated upon Raf activation while NEP levels were downregulated (Fig. 2A). However, the
level of NSE induction at 48 hours after Raf activation was mild, indicating that Raf
activation has more significant effects on AR and NEP regulation. All these effects were
specific to Raf activation because 4-hydroxytamoxifen alone did not induce any similar
effects.
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Interestingly, when NE1.3 and NE1.8 cells were removed from c.s.FBS medium to FBS
medium, these cells exhibited restored expression of AR and strongly repressed ERK1/2
phosphorylation although NSE expression was not as strongly affected, especially in NE1.8
cells (Fig. 2D, first two lanes in each panel). When ǻRaf-1:ER was activated in these cells,
AR expression was again downregulated to a similar level as repressed by hormone
withdrawal (Fig. 2D), further supporting the specific effects of the pathway activation on
AR levels.
Raf-induced AR downregulation is mediated by MEK/ERK but MEK/ERK inhibition cannot
block long term androgen withdrawal-induced AR downregulation in LNCaP cells
Although the MEK/ERK pathway is known as the main effector of Raf, Raf can also
mediate MEK/ERK-independent signaling, e.g., cell death responses [37]. Therefore, we
determined whether MEK/ERK is required for Raf-induced AR downregulation. When Raf
was activated in the presence of the MEK1/2-specific non-competitive inhibitor U0126, AR
downregulation was significantly blocked in LNCaP cells (Fig. 3A). On the other hand,
expression of the constitutively active mutants of MEK1 (ǻN3/S218E/S222D) or MEK2
(ǻN4/S222D/S226D) induced AR downregulation in LNCaP cells (Fig. 3B, first three
lanes), indicating that MEK1/2 activity is necessary and sufficient to mediate Raf-induced
AR downregulation.
The requirement of MEK/ERK for Raf-mediated AR downregulation was further
investigated at ERK1 and ERK2 levels using the RNA interference technique. Lentiviral
shRNA-mediated knockdown of both ERK isoforms resulted in substantial depletion of
ERK1/2 activity, as indicated by phosphorylation of ribosomal S6 kinase (p90RSK), and very
effectively inhibited MEK1/2-mediated AR downregulation (Fig. 3B). p90RSK is an ERK1/2
substrate that serves as a bona fide readout of in vivo ERK1/2 kinase activity [26, 38].
Although ERK1 and ERK2 have overlapping roles in many different biological contexts,
they are also known to have distinct roles for certain biological contexts, e.g., embryonic
development or differentiation [39, 40]. Therefore, we investigated which ERK plays the
key role in the pathway-mediated AR downregulation. When ERK1 and ERK2 were
individually knocked down using two independent siRNA oligomers, ERK2 depletion
generated stronger inhibitory effects on Raf-induced AR downregulation than ERK1
depletion (Fig. 3C), indicating that ERK2 is the stronger effector although ERK1 has
redundant roles.
Nevertheless, despite the sufficient role of the Raf/MEK/ERK pathway, ERK1/2 depletion
or U0126 treatment could not block c.s.FBS-induced AR downregulation in NE1.3 and
NE1.8 cells (data not shown), indicating that the pathway activation is not necessary for the
AR downregulation observed during LNCaP differentiation under a long term androgen
withdrawal condition.
The Raf/MEK/ERK pathway mediates AR downregulation at mRNA and protein levels
We next investigated the mechanism by which the Raf/MEK/ERK pathway mediates AR
downregulation. Our data showed that activation of the pathway, via ectopic expression of
H-RasG12V, B-RafV600E, MEK1CA, or MEK2CA, can also downregulate AR at mRNA
levels in LNCaP cells (Fig. 4A). When the rates of AR downregulation at mRNA and
protein levels were compared at different time points after Raf activation, the rates of
mRNA or protein downregulation were similar for the first 12 hours (Fig. 4B). However,
thereafter, the rates of AR protein downregulation increased and exceeded the rates of
mRNA downregulation, indicating that an additional mechanism(s) is present and mediates
AR downregulation at protein levels as well (Fig. 4B). Indeed, the proteasome inhibitor
MG132 could block Raf-mediated AR downregulation without significantly affecting the
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pathway activity, as indicated by phosphorylation of ERK1/2 and its substrate p90RSK (Fig.
4C, left panel). This inhibitory effect of MG132 was not due to delayed mRNA
downregulation because MG132 treatment further decreased AR mRNA levels in Raf-
activated cells (Fig. 4D); it was previously reported that MG132 suppresses AR transcription
in LNCaP cells [41]. Raf-mediated AR downregulation was also inhibited by bortezomib,
but not by lactacystin, indicating that the inhibitory effect is not common among different
proteasome inhibitors (Fig. 4C, right panel). Furthermore, we could not detect increased AR
ubiquitylation upon Raf activation even in the presence of MG132 (supplemental data 1),
suggesting that proteasome activity may not be directly involved in AR downregulation.
AR downregulation is specifically required for Raf/MEK/ERK-mediated regulation of
p16INK4A, p21CIP1, NSE, and NEP expression
Sustained Raf/MEK/ERK activation can mediate not only NE differentiation [21] but also
cell cycle arrest in LNCaP cells [26], which supports the implication of the pathway
signaling in decreased mitotic activity of NE transdifferentiating LNCaP cells. Because (i)
AR controls G1/S cell cycle progression [14]; (ii) AR depletion is sufficient to induce
growth arrest in LNCaP cells [42–45]; and (iii) AR downregulation was shown to induce NE
differentiation of LNCaP cells [24], we questioned whether AR downregulation is a key
regulatory mechanism for Raf/MEK/ERK-mediated growth inhibitory signaling and NE
differentiation in LNCaP cells. To address this, we determined whether Raf-controlled
expression of cell cycle regulators and NE differentiation could be abrogated by ectopic
expression of AAø, a constitutively active AR that lacks the hormone binding domain [27].
AAø expression did not affect the MEK/ERK pathway activity, as indicated by
phosphorylation of ERK1/2 and p90RSK (Fig. 5A), but it conferred sustained AR
transcriptional activity in cells irrespective of the pathway activation, as determined by the
PSA-luciferase reporter assay (Fig. 5B). Under this condition, Raf-induced NSE expression,
NEP downregulation, and expression of the cyclin-dependent kinase inhibitors, p16INK4A
and p21CIP1, were significantly blocked whereas downregulation of Rb phosphorylation and
E2F1 expression was not affected (Fig. 5A), indicating that AR downregulation is required
to mediate NE differentiation and to regulate a specific subset of the growth arrest signaling
effectors while the pathway can also activate other mechanisms to negatively regulate Rb/
E2F1 activity. Interestingly, despite the sustained AR transcriptional activity in these cells,
as indicated by PSA-luciferase activity (Fig. 5B), PSA protein level was still downregulated
upon Raf activation (Fig. 5A). This PSA downregulation required ERK1/2 because it was
not observed in ERK1/2-depleted cells (Fig. 5C), indicating that the Raf/MEK/ERK
pathway can regulate certain downstream effectors of AR via a separate mechanism
independently of AR downregulation.
Raf/MEK/ERK activation can induce AR downregulation in different PCa cell lines
irrespective of androgen sensitivity
Lastly, we determined whether the Raf/MEK/ERK pathway can also mediate AR
downregulation in other PCa cell lines. AR is expressed in the androgen-sensitive LNCaP,
LAPC4 and MDA-Pca-2b and the androgen-refractory CWR22Rv1 and C4-2 (an androgen-
refractory LNCaP derivative [46]), but not in PC3 and Du145 (Fig. 6A). CWR22Rv1
expressed different sizes of AR proteins that migrate as two major bands on the SDS-PAGE
gel; the faster migrating band was recently shown to contain three different AR isoforms
that lack the ligand binding domain [47, 48]. The basal MEK/ERK activity in these PCa
lines, except for CWR22Rv1 and Du145, was very low, as indicated by ERK1/2
phosphorylation levels (Fig. 6A).
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When the Raf/MEK/ERK pathway was activated using Raf:ER, B-RafV600E, or the
constitutively active MEK2, AR levels were substantially downregulated in C4-2 and
CWR22Rv1 cells (Fig. 6B and 6C), which was accompanied by strong expression of the
cyclin-dependent kinase inhibitors, p21CIP1 or p27KIP1. These data indicate that Raf/MEK/
ERK can also mediate AR downregulation and growth inhibitory signaling in these cell
lines, and that the signaling can occur irrespective of androgen sensitivity. In C4-2 cells, Raf
activation also induced NSE expression and mild NEP downregulation, which is consistent
with the observation in LNCaP (Fig. 6B). Notably, in CWR22Rv1 cells, Raf activation
downregulated not only the full length AR but also the ligand binding domain-truncated AR
splicing variants (Fig. 6C), which are supposed to more potently stimulate androgen-
insensitive growth of PCa cells [47, 48]. By contrast, Raf/MEK/ERK activation did not
affect AR levels in LAPC4 and MDA-Pca-2b cells (data not shown), indicating that
different types of PCa cells have different responsiveness to the pathway activation.
Discussion
Our study demonstrates that, in certain PCa cell types, (i) activation of the Raf/MEK/ERK
pathway occurs in correlation with AR downregulation upon androgen deprivation and is
sufficient, although not necessary, to mediate the AR regulation; (ii) AR downregulation is
required for the pathway-mediated differentiation (i.e., regulation of NSE and NEP
expression) and specific growth arrest signaling (i.e., p16INK4A and p21CIP1 expression but
not Rb/E2F1 regulation); (iii) the pathway can regulate PSA via a mechanism independent
of AR regulation; and (iv) the pathway activation can mediate AR downregulation
irrespective of their hormone sensitivity (Fig. 7).
Our results from an in vitro LNCaP model that mimics NE differentiation in PCa indicate
that Raf/MEK/ERK signaling has a novel role in regulating AR expression. Contrary to
most other castration-resistant PCa types, NE-like PCa cells do not express AR while
exhibiting upregulated ERK1/2 activity. Consistently, these in vivo alterations were
recapitulated in the NE derivatives of LNCaP that were derived from a long term hormone-
deprived culture. Intriguingly, sustained activation of Raf/MEK/ERK was indeed sufficient
for AR downregulation in the parental LNCaP, although inhibition of the pathway did not
restore AR expression in the NE derivatives of LNCaP. This may indicate that not only Raf/
MEK/ERK but also other parallel independent signaling pathways are involved in AR
downregulation during NE differentiation. Indeed, it was previously reported that the PI3K/
AKT/mTOR pathway is also involved in NE differentiation of LNCaP cells [30], and that
ectopic expression of AKT can induce proteasomal degradation of AR via Mdm2 E3 ligase-
mediated ubiquitylation [49]. However, in our study, AKT phosphorylation was only mildly
upregulated in the NE derivatives of LNCaP and use of the PI3K specific inhibitor,
LY294002 or overexpression of a dominant-negative AKT did not restore AR expression in
the cells (data not shown), indicating the presence of additional pathways which remain to
be identified.
It was previously shown that steady-state AR levels and its activity decreases upon
prolonged inhibition of basal Raf/MEK/ERK activity in LNCaP cells [50]. Consistently, we
observed similar effects using the MEK1/2 inhibitor U0126, but not with ERK1/2
knockdown, presumably because of its lower potency than the chemical inhibition.
Intriguingly, our current study demonstrates that AR levels and its activity can also be
downregulated by sustained high Raf/MEK/ERK activity. Taken together, these results
suggest that the Raf/MEK/ERK pathway may have a capability to mediate an opposing
context of AR regulation depending upon different signaling intensity, which is coherent
with the biphasic pathway control on LNCaP cell proliferation (i.e., sustained Raf/MEK/
ERK activation induces cell cycle arrest while depletion of its basal activity also delays cell
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proliferation [26, 50]). Indeed, it is known that different duration and strength of the kinase
cascade signals can lead to distinct, and even opposing, cellular processes [1].
It appears that Raf/MEK/ERK-mediated AR downregulation is mediated via multiple
mechanisms. AR was significantly downregulated at both protein and mRNA levels, while
the rates of downregulation were higher at protein levels. Besides, decreases in AR protein,
but not mRNA, were blocked by the proteasome inhibitors MG132 and bortezomib,
indicating that the pathway also mediates AR downregulation via a mechanism independent
of mRNA regulation and that the mechanisms may require proteasome activity. However,
since increases in AR ubiquitylation were not detected upon Raf activation, proteasomal
degradation does not appear to be a direct mechanism of AR downregulation but may be
indirectly involved. Alternatively, since another proteasome inhibitor lactacystin could not
exert similar inhibitory effects, AR downregulation may rather be due to non-proteasomal
degradation. In support of this possibility, MG132 is known for its additional capability to
inhibit certain non-proteasomal proteases such as calpains and cathepsins [51, 52]. Further
exploration of the mechanism underlying AR downregulation is warranted in a future study.
Our study indicates that the Raf/MEK/ERK pathway-mediated growth inhibition and NE
differentiation can be mediated via mechanisms dependent or independent of AR
downregulation. Ectopic expression of the constitutively active AR could specifically inhibit
Raf-mediated NSE, p16INK4A, and p21CIP1 expression, and NEP downregulation. This is
coherent with the known AR function as a regulator of NE differentiation [24] and G1/S cell
cycle progression in PCa cells [14], and indicates that AR can control the cyclin-dependent
kinase/Rb/E2F1 axis via regulating those cyclin-dependent kinase inhibitors. Expression of
p16INK4A or p21CIP1 can delay cell cycle progression by inhibiting G1/S cyclin-dependent
kinases, which would promote Rb-mediated sequestration of the S-phase transcription factor
E2F1 [14]. Nevertheless, despite the forced AR overexpression, the Raf/MEK/ERK pathway
could still downregulate Rb phosphorylation and E2F1 expression, indicating that the
pathway can mediate growth arrest signaling via additional mechanisms other than AR
downregulation (Fig. 7). Consistently, E2F1 downregulation observed in our study indicates
that the Raf/MEK/ERK pathway can inhibit E2F1 activity via a mechanism in addition to
Rb-mediated E2F1 sequestration. Versatile signaling capability of Raf/MEK/ERK in PCa
cells is further supported by its ability to mediate PSA downregulation independently of AR
downregulation.
Raf/MEK/ERK-mediated AR downregulation in LNCaP and CWR22Rv1 extends the
growth inhibitory context of the pathway signaling previously reported in LNCaP cells [26,
53]. Growth inhibitory MEK/ERK signaling in PCa cells has also been demonstrated in
recent reports showing that ligand-mediated activation of the G-protein-coupled receptor 30
induces growth arrest of PC3 cells, for which MEK/ERK activation is necessary [54], and
that expression of constitutively active MEK1 arrests PC3 cells in culture [55]. A question is
thus raised: what would be the potential significance of such MEK/ERK signaling? The
paradoxical growth inhibitory signaling of Ras or Raf in primary normal cells has been
proposed as an anti-oncogenic cellular mechanism against aberrant pathway activation [32,
56, 57]. Similar growth arrest responses can also be elicited in different cell types, including
malignant tumor cell lines in which aberrant Ras/Raf signaling is rarely detected [26, 33–36,
58, 59], suggesting that various cell types retain such mechanisms. Although not frequent,
oncogenic mutations of Ras and Raf are detected in PCa, primarily from Japanese, Korean
and Chinese men [7–10]. Furthermore, a recent study revealed that chromosomal
rearrangements of Raf genes that can confer neoplastic Raf kinase activity occur in about 1–
2% of human PCa [11]. Indeed, the oncogenic B-RafV600E mutant could drive PCa
development in a transgenic mouse model [60]. Given these growing implications of Ras/
Raf in prostate tumorigenesis, it is conceivable that certain AR-dependent prostate cell types
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may exhibit AR downregulation as a Ras/Raf-associated tumor suppressive mechanism
when the pathway becomes deregulated.
Downregulation of AR has been recognized as a potential therapeutic strategy for PCa
regardless of hormone sensitivity because recurrent PCa cells still depend on AR [15]. For
examples, depletion or inhibition of AR using antisense oligonucleotides [42], neutralizing
antibody [43], hammerhead ribozyme [43], RNA interference [44] and small molecules that
mediate targeted proteolysis of AR [45], could induce growth inhibition and apoptosis in
both androgen-dependent and androgen-independent PCa cells. Our results demonstrate that
the Raf/MEK/ERK pathway is connected to a mechanism that can effectively induce AR
downregulation in a subset of PCa cells regardless of hormone sensitivity and, importantly,
the mechanism induces downregulation of not only full length AR but also the AR variants
that lack the hormone binding domain and are known to more potently stimulate PCa cell
growth [47, 48]. Further investigation of the mechanisms underlying Raf/MEK/ERK-
mediated AR downregulation may lead to the development of a novel means to control AR
levels in PCa cells.
In conclusion, our results demonstrate for the first time that the Raf/MEK/ERK pathway has
a novel role in regulating AR levels in a subset of PCa cells and provide an insight into a
PCa cell response in the face of aberrant pathway activation.
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Abbreviation
AR androgen receptor
c.s.FBS charcoal/dextran-stripped fetal bovine serum
ERK extracellular signal-regulated kinase
MEK mitogen activated protein kinase kinase
NEP neutral endopeptidase
NSE neuron specific enolase
PCa prostate cancer
PSA prostate specific antigen
RSK ribosomal S6 kinase
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Figure 1. Correlation between AR expression and MEK/ERK activation changes during LNCaP
response to androgen withdrawal
(A) AR downregulation in LNCaP cells cultured in c.s.FBS containing medium is a specific
effect of androgen depletion. LNCaP cells maintained in the medium containing c.s.FBS for
6 days were moved to c.s.FBS medium with or without 1 nM R1881 and cultured for 4 days.
Cell lysates were analyzed by Western blotting for expression of AR and NSE.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was detected to validate equal
protein loading. (B) AR downregulation is correlated with ERK1/2 phosphorylation. LNCaP
cells cultured in FBS or c.s.FBS medium for 10 days, and NE1.3 and NE1.8 cells
maintained in c.s.FBS medium were analyzed by Western blotting for expression of AR,
PSA, NSE, NEP, phosphorylated ERK1/2 (pERK1/2), ERK1/2, phosphorylated AKT
(pAKT), and GAPDH. Western blotting results were analyzed by densitometry (right panel).
Data (mean ± standard error) are from three independent experiments and show optical
density normalized for GAPDH levels. P value is < 0.05 for AR, pERK1 and pERK2 in
LNCaP-c.s.FBS compared to those in LNCaP-FBS or NE1.3 and NE1.8, respectively, and P
value is < 0.05 for pAKT in LNCaP-c.s.FBS, NE1.3 and NE1.8, respectively, compared to
that in LNCaP-FBS (Student’s t test).
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Figure 2. Raf activation induces downregulation of AR in LNCaP and its NE derivatives
LNCaP, NE1.3 and NE1.8 cells infected with lentiviral pHAGE (control) or pHAGE-
Raf:ER were treated with 1 ȝM 4-hydroxytamoxifen (4-HT) in FBS medium for 2 days. (A)
Total cell lysates of LNCaP were examined by Western blot analysis for expression of AR,
PSA, NSE, NEP, pERK1/2, and ERK1/2. Cell lysates of NE1.3 or NE1.8 maintained in
c.s.FBS medium were used for comparison. (B) Nuclear and cytoplasmic extracts of
LNCaPRaf cells were compared for AR levels by Western blot analysis. GAPDH and PARP
were used to validate the purity and equal protein loading of the cytoplasmic and nuclear
fractions, respectively. (C) LNCaPRaf cells transfected with PSA-luciferase reporter were
treated with 4-hydroxytamoxifen for indicated time periods before determining luciferase
activity. The reporter assay data (mean ± standard error) are from three independent
experiments and are expressed as percent changes induced by Raf activation relative to the
untreated cells. P value is < 0.05 for Raf activation compared to the control at all time points
(Student’s t test). (D) Total cell lysates of NE1.3 and NE1.8 were examined by Western blot
analysis for expression of the indicated proteins. Uninfected or pHAGE-infected NE1.3 and
NE1.8 cells showed identical responses to FBS medium (data not shown).
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Figure 3. MEK/ERK activation is necessary and sufficient to mediate Raf-induced AR
downregulation, and ERK1 and ERK2 have overlapping roles
(A) LNCaPRaf cells were treated for 1 or 2 days with 1 ȝM 4-hydroxytamoxifen for Raf
activation in the presence or absence of 10 ȝM U0126 (MEK1/2 inhibitor), and examined
for expression of AR, PSA, pERK1/2, and ERK1/2 by Western blot analysis. GAPDH was
detected to validate equal protein loading. Western blotting results were then analyzed by
densitometry (right panel). AR levels, normalized for GAPDH levels, are expressed as
percent changes relative to the basal levels in the untreated cells at day 1. Data (mean ±
standard error) are from three independent experiments. P value for blocking effects of
U0126 is < 0.05 for day 1 and day 2 (Student’s t test). (B) LNCaP cells, co-infected with
lentivirus containing shRNA targeting ERK1 (shERK1) or ERK2 (shERK2), were infected
for 2 days with lentivirus containing constitutively active MEK1 (MEK1CA) or MEK2
(MEK2CA) before Western blot analysis of expression of the indicated proteins.
Phosphorylated p90RSK (pRSK) indicates ERK1/2 activity. The empty pHAGE and pLL3.7
are the controls for MEK expression and ERK knockdown, respectively. Densitometry data
of Western blotting results (right panel, mean ± standard error) are from two independent
experiments. P value for blocking effects of shERK1/2 is < 0.05 for MEK1CA and
MEK2CA (Student’s t test). (C) LNCaPRaf cells, transfected with two different sets of
siRNA that target ERK1 or ERK2, were treated with 1 ȝM 4-hydroxytamoxifen for Raf
activation for 2 days before Western blot analysis of expression of the indicated proteins.
Densitometry data of Western blotting results (right panel, mean ± standard error) are from
two independent experiments. AR levels are expressed as percent changes upon Raf
activation, and data for ERK1 and ERK2 are GAPDH-normalized optical density (OD). P
values for blocking effects of siERK1 and siERK2 are < 0.05 and <0.005, respectively
(Student’s t test).
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Figure 4. Mechanisms of AR downregulation induced by Ras/Raf/MEK/ERK activation
(A) LNCaP cells were infected with the lentivirus containing constitutively active H-
RasG12V, B-RafV600E, MEK1CA, or MEK2CA for 2 days. Expression of AR mRNA was
examined by the real time quantitative polymerase reaction (qPCR) assay. Data (mean ±
standard error) are from a representative experiment performed in triplicate and are
expressed as percent changes relative to the basal levels in the uninfected cells (No virus). P
value is < 0.05 for each treatment compared to the pHAGE control (Student’s t test). (B)
LNCaPRaf cells were treated with 4-hydroxytamoxifen for indicated periods. Changes in
AR mRNA and protein levels were monitored by qPCR and Western blotting. Data (mean ±
standard error) are from a representative experiment performed in triplicate and are
expressed as percent changes relative to the basal levels in the untreated cells. P value at 48
hours is < 0.05, n = 3 (Student’s t test). (C) LNCaPRaf cells were treated with 4-
hydroxytamoxifen for Raf activation for 24 hours in the presence of different doses of
proteasome inhibitors, MG132, bortezomib, and lactacystin. Expression of AR, pERK1/2,
pRSK, and GAPDH was examined by Western blot analysis. Equivalent volume of
Dimethyl sulfoxide (DMSO) was used as the vehicle control. (D) LNCaPRaf cells were
treated with 4-hydroxytamoxifen for Raf activation for 24 hours in the presence of different
doses of MG132. Expression of AR mRNA was examined by qPCR. Data (mean ± standard
error) are from a representative experiment performed in triplicate and are expressed as
percent changes relative to the basal levels in DMSO-treated control.
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Figure 5. Ectopic expression of constitutively active AR mutant inhibits Raf-mediated regulation
of NSE, NEP, p16INK4A, and p21CIP1 expression but not downregulation of Rb phosphorylation
and E2F1 expression
(A) LNCaPRaf cells, infected with the lentivirus containing the AR mutant lacking hormone
binding domain (AAø), or the control empty pHAGE virus, were treated with 1 ȝM 4-
hydroxytamoxifen for Raf activation for 2 days and were examined by Western blot analysis
for expression of AR (endo: endogenous AR; exo: exogenously expressed AR mutant),
PSA, pERK1/2, pRSK, phosphorylated Rb (pRb), E2F1, p16INK4A, p21CIP1, NSE and NEP.
(B) LNCaPRaf cells, infected with the AAø virus or pHAGE, were transfected with PSA-
luciferase reporter and treated with 4-hydroxytamoxifen for indicated time periods before
determining luciferase activity. The reporter assay data (mean ± standard error) are from
three independent experiments and are expressed as percent changes induced by Raf
activation relative to the untreated cells. P value is < 0.05 for AR mutant effects compared
to the pHAGE control at all time points (Student’s t test). (C) LNCaPRaf cells, co-infected
with the shERK1 and shERK2 viruses, and then with the AR mutant lentivirus or pHAGE
virus, were treated with 1 ȝM 4-hydroxytamoxifen for Raf activation for 2 days and were
examined by Western blotting for expression of exogenous AR and PSA.
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Figure 6. Raf activation can induce AR downregulation regardless of hormone sensitivity
(A) Hormone-dependent LNCaP, LAPC4, and MDA-Pca-2b; and hormone-independent
C4-2, CWR22Rv1, PC3 and Du145 lines were examined for the basal expression levels of
AR, AR variants lacking ligand binding domain (LBD), and ERK1/2 phosphorylation. (B
and C) C4-2 and CWR22Rv1 cells were infected with pHAGE-Raf:ER and were treated
with 1 ȝM 4-hydroxytamoxifen (4-HT) for 2 days. Cells were also infected with
constitutively active B-RafV600E or MEK2CA viruses for 2 days. Expression of AR, NSE,
NEP, p21CIP1, p27KIP1 and pERK1/2 was examined by Western blot analysis. pRb, E2F1,
p16INK4A were also observed but were not changed (not shown). GAPDH is the loading
control.
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Figure 7. Raf/EMK/ERK-mediated AR regulation, growth inhibitory signaling, and
differentiation
Constitutively high MEK/ERK activity can mediate AR downregulation, growth inhibitory
signaling and differentiation. In this signaling, AR downregulation is required to control
NSE, NEP, p16INK4A and p21WAF expression (i). However, Rb phosphorylation and
expression of E2F1 can be downregulated independently of AR downregulation (ii).
Decreased AR transcriptional activity leads to PSA downregulation (i) but PSA is also
downregulated via a non-transcriptional mechanism independently of AR downregulation
(ii). Raf/EMK/ERK-mediated AR downregulation is also detected in a subset of PCa cells
regardless of hormone sensitivity.
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